Advertisement

Gene therapy stops bleeding episodes in hemophilia trial

New study represents first clear success against the inherited blood disorder

blood clot
iStock.com/somersault18:24

Researchers have scored their first clear success in using gene therapy to treat hemophilia, an inherited blood disorder. Ten men received a single intravenous infusion of a harmless virus ferrying a gene for factor IX, a blood-clotting protein missing in people with hemophilia B. Up to 18 months later, the men's livers are making, on average, 34% the normal level of factor IX. That's enough that nine of the 10 patients have had no bleeding episodes, researchers report today in The New England Journal of Medicine. What's more, eight of the 10 no longer need factor IX injections every few days. Previous gene therapy trials for hemophilia B didn't go well, either because patients' immune systems destroyed the modified cells or the cells didn't make enough factor IX. In the new trial, sponsored by Spark Therapeutics and Pfizer, researchers gave the patients' liver cells the gene for an unusually potent version of the factor IX protein. That allowed the team to lower the vector dose, minimizing immune responses. Two patients had elevated liver enzymes in reaction to the vector, but those levels came down after they received steroids. Only 20% of hemophilia patients have the B form, but efforts are also underway to use gene therapy to treat the most common type, hemophilia A.


Support nonprofit science journalism

Help News from Science publish trustworthy, high-impact stories about research and the people who shape it. Please make a tax-deductible gift today.

Donate

Not Now

Thank you for reading News fromScience.

You have reached your limit of 3 free news stories in the past 30 days.

To gain unlimited access to News fromScience, pleaseLog inor subscribe to News from Science.

AAAS Members canLog infor unlimited access.

$2.99/Month$25/YearFrequently Asked Questions